Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer

NCT02792842 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Postoperative Stage II/III Colon Cancer

Interventions

DRUG: ART-123 (3-day ART)
DRUG: ART-123 (1-day ART)
DRUG: Placebo

Sponsor

Asahi Kasei Therapeutics Corporation